Small cell lung cancer tumours

Higashiyama M, Doi O, Kodama K, Yokouchi H, Tateishi R (1996) Bcl-2 oncoprotein expression is increased especially in the portions of small cell carcinoma within the combined type of small cell lung cancer. Tumour Biol 17 341-344... 

Tumours of the central nervous system Renal cell carcinoma Non-small-cell lung cancer... 

Koukourakis M, Giatromanolaki A, Kakolyris S, O Byrne KJ, Apostolikas N, Skarlatos J, et al. Different patterns of stromal and cancer cell thymidine phosphorylase reactivity in non-small-cell lung cancer Impact on tumour neoangiogenesis and survival. Br J Cancer 1998 77 1696-1703. 

DHA-paclitaxel (Taxoprexin ) 62 (Luitpold) is being evaluated in a Phase III trial for the treatment of advanced non-small cell lung cancer in combination with carboplatin,136 as well against a variety of cancers in Phase II trials. DHA-paclitaxel 62,137 139 which is the C-2 docosahexaenoic acid (DHA) ester of paclitaxel 60, was licensed by Luitpold from Protarga in 2003. Polyunsaturated fatty acids have been reported to be taken up by tumour cells at a higher rate than normal cells and, as a consequence, a polyunsaturated fatty ester such as DHA-paclitaxel 62 may be absorbed more specifically in tumour cells. In preclinical studies, DHA-paclitaxel 62 exhibited increased activity in mice xenograft models and was more stable in vivo than paclitaxel 60. However, DHA-paclitaxel 62 may still suffer from efflux problems associated with paclitaxel 60 and docetaxel resistant tumours. 

Yanagisawa, K. et al., Proteomic patterns of tumour subsets in non-small-cell lung cancer, Lancet, 362, 433, 2003. 

Yang, W., Zhang, Y., Fu, Z., Sun, X., Mu, D., Yu, J. Imaging prohferation of (1)(8)F-FLT PET/CT correlated with the expression of micro vessel density of tumour tissue in non-small-cell lung cancer. European Journal of Nuclear Medicine and Molecular Imaging 39(8), 1289-1296 (2012)... 

In a large variety of advanced carcinomas curative radiotherapy is combined with chemotherapy. Experimental observations and some clinical studies indicate that chemotherapy as a single modality can induce accelerated repopulation in tumours (reviewed in Davis and Tannock 2000 Kim and Tannock 2005). Induced repopulation by induction chemotherapy may possibly explain the inferior results of induction chemotherapy before radiotherapy compared with concurrent chemo-radiation in patients with non-small cell lung cancer (Fournel et al. 2005 Furuse et al. 1999 Zatloukal et al. 2004). 

The evidence of a time factor of concurrent chemo-radiation remains a controversial issue. A randomized clinical trial in patients with limited disease small cell lung cancer (SCLC) treated with chemoradiation demonstrated a significantly higher local tumour control when OTT was reduced from 33 to 19 days (Turrisi etal. 1999). A meta-analysis of four randomized clinical trials in patients with Umited disease SCLC revealed that OTT is the most important predictive factor for outcome after chemoradiation (De Ruysscher etal. 2006). In contrast to the results of this meta-analysis. 

Greco C, Rosenzweig K, Cascini GL et al (2007) Current status of PET/CT for tumour volume definition in radiotherapy treatment planning for non-small cell lung cancer (NSCLC). Lung Cancer 57 125-134... 

Kularatne, B.Y. Lorigan, P. Browne, S. Suvarna, S.K. Smith, M.O. Lawry, J. (2002), Monitoring tumour cells in the peripheral blood of small cell lung cancer patients. Cytometry, 50 160-167. 

---